Background: There have been few clinical studies of the role of regulatory T cells (Tregs) in halo formation of halo nevus. Objective: To evaluate the clinicopathologic features and the presence of Tregs in halo nevi. Methods: We analyzed 30 halo nevi and performed immunohistochemical analysis using antibodies against CD4, CD8, CD25 and Foxp3. We also performed double immunohistochemical staining for Foxp3 and CD25. Results: We found significant increases in Foxp3+ Tregs, and the shorter the halo nevus duration, the more Foxp3+ Tregs were detected. Also, the ratio of Foxp3 to CD8 T cells was increased in early stages of halo nevi. Double immunohistochemical staining suggested that the Tregs in the halo nevi were CD25+Foxp3+ T cells. Conclusions: Foxp3+ Tregs were greatly increased in the halo nevi. The shorter the halo nevi duration, the more Foxp3+ Tregs were involved in the earlier developmental stages of halo nevi.

Keywords:
Halo nevi, Foxp3 T cells
1.
Langer K, Konrad K: Congenital melanocytic nevi with halo phenomenon: report of two cases and a review of the literature. J Dermatol Surg Oncol 1990;16:377–380.
2.
Kopf AW, Morrill SD, Silberberg I: Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965;92:14–35.
3.
Rhodes AR: Benign neoplasias and hyperplasia of melanocytes; in Freedberg IM (ed): Fitzpatrick’s Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 1999, p 1034.
4.
El Andaloussi A, Lesniak MS: CD4+CD25+ Foxp3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007;83:145–152.
5.
Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA: The development and function of regulatory T cells. Cell Mol Life Sci 2009;66:2603–2622.
6.
Robinson DS: Regulatory T cells and asthma. Clin Exp Allergy 2009;39:1314–1323.
7.
de Boer OJ, van der Loos CM, Teeling P, van der Wal AC, Teunissen MB: Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatosis. J Histochem Cytochem 2007;55:891–898.
8.
Klarquist J, Derma CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC: Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010;23:276–286.
9.
Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubbert L, Bachelez H, Kourilsky P, Ferradini L: Foxp3 expressing CD4+CD25(high) regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444–1453.
10.
Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639–3646.
11.
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766–4772.
12.
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756–2761.
13.
Kawaida H, Kono K, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Ooi A, Fujii H: Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151–157.
14.
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457–2464.
15.
Roncador G, Darcia JF, Maestre L, Lucas E, Menarguez J, Ohshima K, Nakamura S, Banhan AH, Piris MA: FOXP3, a selective marker for a subset of adult T-cell leukemia/lymphoma. Leukemia 2005;19:2247–2253.
16.
Berger RS, Vorhees JJ: Multiple congenital giant nevocellular nevi with halo: clinical and electron microscopic study. Arch Dermatol 1974;104:515–521.
17.
Flank SB, Cohen JH: The halo nevus. Arch Dermatol 1964;89:367–373.
18.
Graham JH, Fogel NA, Burgoon CF: Multiple nonpigmented nevi in a negro child. Arch Dermatol 1963;88:313–319.
19.
Rados J, Pastar Z, Lipozencić J, Ilić I, Stulhofer Buzina D: Halo phenomenon with regression of acquired melanocytic nevi: a case report. Acta Dermatovenerol Croat 2009;17:139–143.
20.
Mckee P, Calonje E, Granter SR: Pathology of the skin with clinical correlation. Philadelphia, Elsevier Mosby, 2005, pp 1266–1268.
21.
Anstey AV: Disorders of skin color; in Burns T, Breathnach S, Cox N, Griffiths C (eds): Rook’s Textbook of Dermatology. Oxford, UK, Wiley-Blackwell, 2010, pp 49–50.
22.
Wayte DM, Helwig EB: Halo nevi. Cancer 1968;22:69–90.
23.
Lerner AB: On the etiology of vitiligo and gray hair. Am J Med 1971;51:141–147.
24.
Bergman W, Willemze R, de-Graaff-Reitsma C, Ruiter DJ: Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi. J Invest Dermatol 1985;85:25–29.
25.
Ortonne JP, Mosher DB, Fitzpatrick TB: Vitiligo and other hypomelanoses of hair and skin. New York, Plenum Publishing, 1983, p 567.
26.
Zeff RA, Freitag A, Grin CM, Grant-Kels JM: The immune response in halo nevi. J Am Acad Dermatol 1997;37:620–624.
27.
Tokura Y, Yamamaka K, Wakita H, Kurokawa S, Horiguchi D, Usui A, Sayama S, Takigawa M: Halo congenital nevus undergoing spontaneous regression. Involvement of T-cell immunity in involution and presence of circulating anti-nevus cell IgM antibodies. Arch Dermatol 1994;130:1036–1041.
28.
Bayer-Garner IB, Ivan D, Schwartz MR, Tschen JA: The immunopathology of regression in benign lichenoid keratosis, keratoacanthoma and halo nevus. Clin Med Res 2004;2:89–97.
29.
Moretti S, Spallanzani A, Pinzi C, Prignano F, Fabbri P: Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment? J Cutan Pathol 2007;34:301–308.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.